查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1672784

肺炎链球菌疫苗市场按疫苗类型、目标族群、接种途径、通路和地区划分

Pneumococcal Vaccines Market, By Vaccine Type, By Target Population, By Route of Administration, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2025 年全球肺炎链球菌疫苗市场规模估计为 93.8 亿美元，预计到 2032 年将达到 132.9 亿美元，2025 年至 2032 年的复合年增长率为 5.1%。

报告范围 报告详细信息
基准年 2024 2025 年市场规模 93.8亿美元
效能资料 从 2020 年到 2024 年 预测期 2025 至 2032 年
预测期：2025-2032年复合年增长率： 5.10% 2032 年价值预测 132.9亿美元
数字。 2025 年肺炎链球菌疫苗市场占有率（按地区划分）
肺炎链球菌疫苗市场-IMG1

全球肺炎链球菌疫苗市场的成长受到世界范围内肺炎球菌疾病发病率上升以及世界各国政府实施的疫苗接种计划增加等因素的推动。此外，人们对肺炎球菌疫苗接种认识的不断提高也推动了市场的成长。然而，开发和生产肺炎球菌疫苗的高成本可能会阻碍市场成长。正在进行的开发经济实惠且有效疫苗的研究工作可能会在不久的将来提供新的机会。

市场动态：

全球肺炎球菌疫苗市场的成长主要受到肺炎、脑膜炎和肺炎球菌肺炎引起的其他严重感染疾病在全球日益流行的推动。根据世界卫生组织（WHO）的数据，肺炎是五岁以下儿童五大死因之一。此外，增加政府资金和透过国家免疫计划推广疫苗接种计划的倡议可能会推动市场成长。然而，肺炎球菌疫苗的高研发和製造成本可能会阻碍市场扩张。正在进行的评估新型多效价肺炎链球菌製剂的安全性和有效性的临床试验可能会推动市场成长。新兴经济体已经发达了医疗保健基础设施，这对市场进入者来说是一个巨大的机会。

本研究的主要特点

本报告对全球肺炎球菌疫苗市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设 2024 年为基准年。

它还强调了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。

它还提供了关于市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。

全球肺炎球菌疫苗市场的主要企业是根据公司亮点、产品系列、关键亮点、绩效和策略等参数进行分析的。

主要公司包括辉瑞、默克、葛兰素史克、赛诺菲等。

本报告提供的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。

全球肺炎球菌疫苗市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。

目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要

第三章市场动态、法规与趋势分析

  • 市场动态
  • 影响分析
  • 主要亮点
  • 监管情景
  • 产品发布/核准
  • PEST分析
  • PORTER 分析
  • 併购情景

4. 2020 年至 2032 年全球肺炎链球菌疫苗市场（以疫苗类型划分）（十亿美元）

  • 肺炎链球菌结合疫苗（PCV）
  • 肺炎链球菌多醣体疫苗（PPV）

5. 2020 年至 2032 年全球肺炎链球菌疫苗市场（以目标族群划分）（十亿美元）

  • 成人（65 岁以上）
  • 儿童（5岁以下）
  • 高危险群成人（18-64 岁）

6. 2020 年至 2032 年全球肺炎链球菌疫苗市场（依给药途径划分）（十亿美元）

  • 肌肉注射
  • 皮下

7. 2020-2032 年全球肺炎链球菌疫苗市场按分销管道划分（十亿美元）

  • 医院药房
  • 零售药局
  • 网路药局

8. 2020 年至 2032 年全球肺炎链球菌疫苗市场（按地区划分）（十亿美元）

  • 北美洲
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第九章 竞争格局

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc（GSK）
  • Sanofi
  • CSL Limited
  • Serum Institute of India Pvt. Ltd.
  • Vaxcyte, Inc.
  • Astellas Pharma Inc.
  • Panacea Biotec Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biovac
  • Bharat Biotech
  • Inovio Pharmaceuticals, Inc.
  • Hilleman Laboratories Pvt. Ltd

第 10 章分析师建议

第 11 章 参考文献与调查方法

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI2295

Global Pneumococcal Vaccines Market is estimated to be valued at USD 9.38 Bn in 2025 and is expected to reach USD 13.29 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 9.38 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.10% 2032 Value Projection: USD 13.29 Bn
Figure. Pneumococcal Vaccines Market Share (%), By Region 2025
Pneumococcal Vaccines Market - IMG1

Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.

Market Dynamics:

Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.

Key features of the study:

This report provides in-depth analysis of the global pneumococcal vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pneumococcal vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

  • By Vaccine Type
    • Pneumococcal Conjugate Vaccines (PCVs)
    • PCV13 (Prevnar 13/Prevenar 13)
    • PCV10 (Synflorix)
    • PCV7 (Prevnar/Prevenar)
    • Pneumococcal Polysaccharide Vaccines (PPVs)
    • PPSV23 (Pneumovax 23)
    • PPSV14 (Pneumo 14)
  • By Target Population
    • Adults (>= 65 years)
    • Children (< 5 years)
    • High-Risk Adults (18-64 years)
  • By Route of Administration
    • Intramuscular
    • Subcutaneous
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Key Players Insights
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc (GSK)
    • Sanofi
    • CSL Limited
    • Serum Institute of India Pvt. Ltd.
    • Vaxcyte, Inc.
    • Astellas Pharma Inc.
    • Panacea Biotec Ltd.
    • Walvax Biotechnology Co., Ltd.
    • Beijing Minhai Biotechnology Co., Ltd.
    • Merck KGaA
    • Takeda Pharmaceutical Company Limited
    • AbbVie Inc.
    • Novartis AG
    • Johnson & Johnson
    • Biovac
    • Bharat Biotech
    • Inovio Pharmaceuticals, Inc.
    • Hilleman Laboratories Pvt. Ltd

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Pneumococcal Vaccines Market, By Vaccine Type
    • Global Pneumococcal Vaccines Market, By Target Population
    • Global Pneumococcal Vaccines Market, By Route of Administration
    • Global Pneumococcal Vaccines Market, By Distribution Channel
    • Global Pneumococcal Vaccines Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pneumococcal Conjugate Vaccines (PCVs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • PCV13 (Prevnar 13/Prevenar 13)
    • PCV10 (Synflorix)
    • PCV7 (Prevnar/Prevenar)
  • Pneumococcal Polysaccharide Vaccines (PPVs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • PPSV23 (Pneumovax 23)
    • PPSV14 (Pneumo 14)

5. Global Pneumococcal Vaccines Market, By Target Population, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adults (>= 65 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Children (< 5 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • High-Risk Adults (18-64 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Pneumococcal Vaccines Market, By Route of Administration, 2020-2032, (USD Bn)

  • Intramuscular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Pneumococcal Vaccines Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021- 2032, (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc (GSK)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • CSL Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Serum Institute of India Pvt. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Vaxcyte, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Panacea Biotec Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Walvax Biotechnology Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Beijing Minhai Biotechnology Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biovac
  • Bharat Biotech
  • Inovio Pharmaceuticals, Inc.
  • Hilleman Laboratories Pvt. Ltd

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us